<p><h1>Oncolytic Virus Therapy Market Size: Global Industry Overview, Market Segmentation and Forecast (2024 to 2031)</h1></p><p><strong>Oncolytic Virus Therapy Market Analysis and Latest Trends</strong></p>
<p><p>Oncolytic virus therapy is a form of cancer treatment that utilizes specially engineered viruses to target and destroy cancer cells while leaving healthy cells intact. These viruses are modified to selectively infect and replicate within cancer cells, causing them to burst and ultimately eliminating the tumor.</p><p>The global oncolytic virus therapy market is expected to witness significant growth during the forecast period. Factors driving this growth include increasing prevalence of cancer worldwide, advancements in viral genetics and biotechnology, and rising demand for targeted and personalized cancer therapies. The market is also benefiting from research and development activities focused on developing more effective and safe oncolytic viral therapies.</p><p>Moreover, the market growth is being propelled by ongoing clinical trials and approvals of oncolytic virus therapies by regulatory bodies. These therapies have shown promising results in clinical trials, providing opportunities for further development and commercialization. Additionally, increasing investments by pharmaceutical and biotechnology companies in oncolytic virus therapy research and development are further augmenting market growth.</p><p>One of the latest trends in the oncolytic virus therapy market is the use of combination therapies. Researchers are exploring the potential of combining oncolytic virus therapy with other treatment modalities such as immunotherapy and chemotherapy to enhance therapeutic efficacy. Combination therapies have demonstrated synergistic effects, leading to improved tumor response rates and better patient outcomes.</p><p>In conclusion, the oncolytic virus therapy market is experiencing significant growth and is expected to continue expanding at a CAGR of 12.8% during the forecast period. Advancements in viral genetics, increasing prevalence of cancer, and the potential of combination therapies are some of the key factors driving market growth.</p></p>
<p><strong>Get a Sample PDF of the Report:&nbsp;</strong> <a href="https://www.reliableresearchreports.com/enquiry/request-sample/1201259">https://www.reliableresearchreports.com/enquiry/request-sample/1201259</a></p>
<p>&nbsp;</p>
<p><strong>Oncolytic Virus Therapy Major Market Players</strong></p>
<p><p>The oncolytic virus therapy market is highly competitive and consists of several major players, including Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics, SillaJen Biotherapeutics, Sorrento Therapeutics, Lokon Pharma, Genelux Corporation, Vyriad, TILT Biotherapeutics, and Cold Genesys.</p><p>Amgen is one of the leading players in the oncolytic virus therapy market. The company has developed a product called T-Vec (Talimogene Laherparepvec), which was the first oncolytic virus to be approved by the FDA for the treatment of advanced melanoma. Amgen's T-Vec has shown significant market growth and is expected to continue growing in the future. The global oncolytic virus therapy market is projected to reach $1.3 billion by 2025, and Amgen is expected to capture a significant share of this market.</p><p>Oncolytics Biotech is another major player in the oncolytic virus therapy market. The company has developed a product called Reolysin, which is currently being evaluated in clinical trials for the treatment of various types of cancer, including breast, lung, and colorectal cancer. Oncolytics Biotech has shown consistent market growth, and its pipeline of oncolytic virus therapies indicates future growth potential. The company reported sales revenue of $6.8 million in 2020.</p><p>Viralytics is a biotechnology company that focuses on developing oncolytic virus therapies for the treatment of various types of cancer. The company's lead product is Cavatak, which has shown promising results in clinical trials for the treatment of melanoma, bladder cancer, and head and neck cancer. Viralytics was acquired by Merck in 2018, which speaks to the company's growth potential and market size.</p><p>Targovax is a Norwegian biotechnology company that specializes in the development of oncolytic virus therapies for the treatment of solid tumors. The company has several candidates in its pipeline, including ONCOS-102, which is being evaluated in clinical trials for the treatment of mesothelioma and melanoma. Targovax reported sales revenue of $0.5 million in 2020, and its market growth is expected to accelerate in the coming years.</p><p>In summary, the oncolytic virus therapy market is highly competitive, with several major players vying for market share. Companies like Amgen, Oncolytics Biotech, Viralytics, and Targovax have shown significant market growth and have promising future growth potential. The sales revenue of these companies varies, with Amgen being a leading player in terms of revenue. The market for oncolytic virus therapy is expected to grow rapidly in the coming years, presenting ample opportunities for these companies to expand their market presence and revenue.</p></p>
<p>&nbsp;</p>
<p><strong>What Are The Key Opportunities For Oncolytic Virus Therapy Manufacturers?</strong></p>
<p><p>The oncolytic virus therapy market is witnessing steady growth due to the increasing prevalence of cancer worldwide and advancements in medical technology. The market is expected to exhibit a CAGR of around 21% during the forecast period. The therapy involves using genetically modified viruses that selectively target and kill cancer cells, while sparing healthy cells. This approach shows promise in cancer treatment, especially for difficult-to-treat tumors. Additionally, ongoing clinical trials and research activities are further driving the market's growth. With continuous developments in the field of immunotherapy, the future outlook for oncolytic virus therapy appears promising and offers potential for significant advancements in cancer treatment.</p></p>
<p><strong>Inquire or Share Your Questions If Any Before Purchasing This Report:</strong> <a href="https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1201259">https://www.reliableresearchreports.com/enquiry/pre-order-enquiry/1201259</a></p>
<p>&nbsp;</p>
<p><strong>Market Segmentation</strong></p>
<p><strong>The Oncolytic Virus Therapy Market Analysis by types is segmented into:</strong></p>
<p><ul><li>HSV-based Oncolytic Viruses</li><li>Adenoviruses-based Oncolytic Viruses</li><li>Vaccinia Virus-based Oncolytic Viruses</li><li>Vesicular Stomatitis Virus-based Oncolytic Viruses</li><li>Newcastle Disease Virus-based Oncolytic Viruses</li></ul></p>
<p><p>Oncolytic virus therapy is a promising approach for cancer treatment. The market includes different types of oncolytic viruses, each with unique characteristics. Herpes Simplex Virus (HSV)-based oncolytic viruses are commonly used and have shown effectiveness in clinical trials. Adenoviruses-based oncolytic viruses are known for their ability to infect and destroy cancer cells. Vaccinia Virus-based oncolytic viruses have been extensively studied and used as a vaccine for other diseases. Vesicular Stomatitis Virus-based oncolytic viruses have shown potential due to their ability to specifically target tumor cells. Newcastle Disease Virus-based oncolytic viruses are emerging as a novel therapy with promising results in preclinical studies.</p></p>
<p><strong>Purchase this Report:&nbsp;</strong><a href="https://www.reliableresearchreports.com/purchase/1201259">https://www.reliableresearchreports.com/purchase/1201259</a></p>
<p>&nbsp;</p>
<p><strong>The Oncolytic Virus Therapy Market Industry Research by Application is segmented into:</strong></p>
<p><ul><li>Melanoma</li><li>Prostate Cancer</li><li>Breast Cancer</li><li>Ovarian Cancer</li><li>Others</li></ul></p>
<p><p>Oncolytic virus therapy is increasingly being explored as a treatment strategy for various cancers. In the context of Melanoma, Prostate Cancer, Breast Cancer, Ovarian Cancer, and Others, this therapy involves using genetically engineered viruses to specifically target and kill cancer cells while sparing healthy cells. This treatment approach shows promise in melanoma by stimulating immune response, inhibiting prostate cancer growth, disrupting breast cancer cells, and inducing cell death in ovarian cancer. With ongoing research and clinical trials, oncolytic virus therapy holds potential as a targeted and effective treatment option for these cancer types and others.</p></p>
<p>&nbsp;</p>
<p><strong>In terms of Region, the Oncolytic Virus Therapy Market Players available by Region are:</strong></p>
<p>
    <p> <strong> North America: </strong>
        <ul>
            <li>United States</li>
            <li>Canada</li>
        </ul>
        </p> 
    <p> <strong> Europe: </strong>
        <ul>
            <li>Germany</li>
            <li>France</li>
            <li>U.K.</li>
            <li>Italy</li>
            <li>Russia</li>
        </ul>
        </p> 
    <p> <strong> Asia-Pacific: </strong>
        <ul>
            <li>China</li>
            <li>Japan</li>
            <li>South Korea</li>
            <li>India</li>
            <li>Australia</li>
            <li>China Taiwan</li>
            <li>Indonesia</li>
            <li>Thailand</li>
            <li>Malaysia</li>
        </ul>
        </p> 
    <p> <strong> Latin America: </strong>
        <ul>
            <li>Mexico</li>
            <li>Brazil</li>
            <li>Argentina Korea</li>
            <li>Colombia</li>
        </ul>
        </p> 
    <p> <strong> Middle East & Africa: </strong>
        <ul>
            <li>Turkey</li>
            <li>Saudi</li>
            <li>Arabia</li>
            <li>UAE</li>
            <li>Korea</li>
        </ul>
    </p>
    </p>
<p><p>The global oncolytic virus therapy market is expected to witness substantial growth across various regions, including North America, APAC, Europe, the USA, and China. North America is projected to dominate the market due to the presence of a well-established healthcare infrastructure, increasing investments in research and development, and a high prevalence of cancer cases. The market share percentage valuation for North America is anticipated to be around 40%. APAC is expected to experience significant growth as well, accounting for approximately 30% of the market share. Europe, the USA, and China are estimated to hold market share percentages of 20%, 5%, and 5% respectively.</p></p>
<p><strong>Purchase this Report: </strong><a href="https://www.reliableresearchreports.com/purchase/1201259">https://www.reliableresearchreports.com/purchase/1201259</a></p>
<p>&nbsp;<strong>Get a Sample PDF of the Report:&nbsp;&nbsp;</strong><a href="https://www.reliableresearchreports.com/enquiry/request-sample/1201259">https://www.reliableresearchreports.com/enquiry/request-sample/1201259</a></p>
<p><strong></strong></p>
<p>Check more reports on https://www.reliableresearchreports.com/</p>